(EP-NEN) using a standardized DLL3 IHC assay. DLL3 expression is enriched in SCLC, LCNEC along with combined histology lung cancers. Moreover, we find a wide range of DLL3 expression in high-grade EP-NEN. We describe heterogenous DLL3 expression not only in SCLC but also in different ...
As of April 21, 2023, the median DOR had not yet been reached and responses appeared to be durable. In a total of 107 patients, 5 dose-limiting toxicities (DLTs) occurred; 2 patients experienced grade 3 or 4 cytokine release syndrome, 1 had grade 3 confusion state, 1 had grade...
Results showed that the maximum tolerated dose (MTD) was not reached in the overall population (n = 107), although 5 dose-limiting toxicities (DLTs) occurred––all reversible––including grade 3/4 cytokine release syndrome (CRS, n = 2), grade 3 confusional state (n...